AUTONOMIC AND ENDOTHELIAL DYSFUNCTION IN EXPERIMENTAL DIABETES

Diabetes mellitus (DM) is widely recognized as the most severe metabolic disease associated with increased cardiovascular morbidity and mortality. The generation of reactive oxygen species (ROS) is a major event causally linked to the development of cardiovascular complications throughout the evolution of DM. Recently, monoamine oxidases (MAOs) at the outer mitochondrial membrane, with 2 isoforms, MAO-A and MAO-B, have emerged as novel sources of constant hydrogen peroxide (H2O2) production in the cardiovascular system via the oxidative deamination of biogenic amines and neurotransmitters. Whether MAOs are mediators of endothelial dysfunction in DM is unknown, and so we studied this in a streptozotocin-induced rat model of diabetes. MAO expression (mRNA and protein) was increased in both arterial samples and hearts isolated from the diabetic animals. Also, H2O2 production (ferrous oxidation – xylenol orange assay) in aortic samples was significantly increased, together with an impairment of endothelium-dependent relaxation (organ-bath studies). MAO inhibitors (clorgyline and selegiline) attenuated ROS production by 50% and partially normalized the endothelium-dependent relaxation in diseased vessels. In conclusion, MAOs, in particular the MAO-B isoform, are induced in aortas and hearts in the streptozotocin-induced diabetic rat model and contribute, via the generation of H2O2, to the endothelial dysfunction associated with experimental diabetes.

Download Full-text

Effect of ruthenium red, a ryanodine receptor antagonist in experimental diabetes induced vascular endothelial dysfunction and associated dementia in rats

Physiology & Behavior ◽

10.1016/j.physbeh.2016.05.052 ◽

2016 ◽

Vol 164 ◽

pp. 140-150 ◽

Cited By ~ 9

Author(s):

Swati Jain ◽

Bhupesh Sharma

Keyword(s):

Endothelial Dysfunction ◽

Receptor Antagonist ◽

Ryanodine Receptor ◽

Experimental Diabetes ◽

Ruthenium Red ◽

Vascular Endothelial ◽

Vascular Endothelial Dysfunction

Download Full-text

P172Monoamine oxidase inhibition corrects endothelial dysfunction in experimental diabetes

Cardiovascular Research ◽

10.1093/cvr/cvu082.108 ◽

2014 ◽

Vol 103 (suppl 1) ◽

pp. S30.3-S30 ◽

Cited By ~ 4

Author(s):

A Sturza ◽

L Noveanu ◽

O Duicu ◽

DM Muntean

Keyword(s):

Endothelial Dysfunction ◽

Experimental Diabetes ◽

Oxidase Inhibition

Download Full-text

Synthesis of docosahexaenoic acid–loaded silver nanoparticles for improving endothelial dysfunctions in experimental diabetes

Human & Experimental Toxicology ◽

10.1177/0960327119843586 ◽

2019 ◽

Vol 38 (8) ◽

pp. 962-973 ◽

Cited By ~ 11

Author(s):

JS Hussein ◽

W Rasheed ◽

T Ramzy ◽

M Nabeeh ◽

M Harvy ◽

...

Keyword(s):

Fatty Acids ◽

Silver Nanoparticles ◽

Electron Microscope ◽

Endothelial Dysfunction ◽

Cell Membrane ◽

Docosahexaenoic Acid ◽

Experimental Diabetes ◽

Diabetic Group ◽

Control Group ◽

Albino Rats

Objective: To investigate the ability of docosahexaenoic acid (DHA)-loaded silver nanoparticles (AgNPs) in facilitating the incorporation of DHA in the cell membrane, improve cell membrane structure, and attenuate endothelial dysfunction in experimental diabetes. Methods: DHA/AgNPs were prepared using a nanoprecipitation technique. Fifty male albino rats were used in this study; 10 of them were served as the control group and 40, as the experimental groups, were injected with streptozotocin. Then, the experimental groups were subdivided into diabetic, diabetic treated with DHA, diabetic treated with AgNPs, and diabetic treated with DHA/AgNPs groups. Results: DHA/AgNPs have small spherical size as proved from ultraviolet–visible spectroscopy, transmission electron microscope, dynamic light scattering, and scanning electron microscope techniques. Cell membrane cholesterol and triglycerides showed a significant elevation in the diabetic group compared to the control, but treatment with DHA and DHA/AgNPs caused a significant reduction in both. Treatment with AgNPs and DHA/AgNPs caused a significant improvement in asymmetric dimethylarginine and nitric oxide levels compared to the diabetic group. Cell membrane fatty acids showed that omega-6 polyunsaturated fatty acids (PUFAs) were significantly elevated, while omega-3 PUFA were significantly reduced in the diabetic group compared to the control. There is a significant improvement in the levels of fatty acids in all groups after treatment with DHA, silver, or DHA/AgNPs. Conclusion: DHA/AgNPs are potent agents for the improvement of diabetic complication and endothelial dysfunction in experimental diabetes.

Download Full-text